15.03
2.31 (18.16%)
| Penutupan Terdahulu | 12.72 |
| Buka | 12.72 |
| Jumlah Dagangan | 411,130 |
| Purata Dagangan (3B) | 181,583 |
| Modal Pasaran | 932,301,888 |
| Harga / Buku (P/B) | 3.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Sep 2025 |
| EPS Cair (TTM) | -0.790 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.21% |
| Nisbah Semasa (MRQ) | 29.71 |
| Aliran Tunai Operasi (OCF TTM) | -41.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.93 M |
| Pulangan Atas Aset (ROA TTM) | -11.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | GH Research PLC | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.63 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.88% |
| % Dimiliki oleh Institusi | 68.88% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lynx1 Capital Management Lp | 31 Mar 2025 | 6,443,940 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (HC Wainwright & Co., 166.13%) | Beli |
| Median | 39.00 (159.48%) | |
| Rendah | 29.00 (Guggenheim, 92.95%) | Beli |
| Purata | 36.00 (139.52%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 11.10 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JMP Securities | 24 Jun 2025 | 39.00 (159.48%) | Beli | 12.54 |
| Guggenheim | 09 May 2025 | 29.00 (92.95%) | Beli | 10.38 |
| HC Wainwright & Co. | 09 May 2025 | 40.00 (166.13%) | Beli | 10.38 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jun 2025 | Pengumuman | GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule |
| 15 May 2025 | Pengumuman | GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting |
| 08 May 2025 | Pengumuman | GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |